Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | ARG2 | P78540 | 1/20 | 0.41 |
| ▸ | G6PC1 | P35575 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL437686 | 1.00 | MAOB (0.46) | MAOBCA1CA2ARG2G6PC1 | |
| SCHEMBL437687 | 1.00 | MAOB (0.46) | MAOBCA1CA2ARG2G6PC1 | |
| SCHEMBL29626995 | 0.88 | LMNA (0.56) | LMNA | |
| SCHEMBL6548028 | 0.88 | TP53 (0.46) | KDM1A | |
| SCHEMBL6548125 | 0.88 | MEN1 (0.43) | LMNA | |
| SCHEMBL6547171 | 0.88 | GPR52 (0.44) | MAOB | |
| SCHEMBL5918848 | 0.87 | TRPA1 (0.56) | MAOBLMNA | |
| SCHEMBL9588485 | 0.87 | GPR52 (0.43) | MAOB | |
| SCHEMBL5918844 | 0.87 | TRPA1 (0.56) | MAOBLMNA | |
| SCHEMBL5918838 | 0.87 | TRPA1 (0.56) | MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655307-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | Givaudan SA (CH) | 2013-10-30 | — | — | EP | claimed |
| WO-2012085287-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | GIVAUDAN SA (CH) | 2012-06-28 | — | — | WO | claimed |
| US-20160128933-A1 | Therapeutic Methods and Compositions | SHANG TIANGANG (US) | 2016-05-12 | — | — | US | disclosed |
| EP-2655307-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | Givaudan SA (CH) | 2013-10-30 | — | — | EP | disclosed |
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2012085287-A1 | COMPOUNDS CAPABLE OF RELEASING FRAGRANT COMPOUNDS | GIVAUDAN SA (CH) | 2012-06-28 | — | — | WO | disclosed |
| WO-2012012498-A9 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012012498-A2 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | PULMATRIX, INC. (US) | 2012-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203715-A1 | USE OF TRP CHANNEL AGONISTS TO TREAT INFECTIONS | TRPV1, TRPC4, TRPC3 | MAOB 1236/4885CA1 2372/4885CA2 474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.